# LY6K

## Overview
LY6K is a gene that encodes the protein lymphocyte antigen 6 family member K, which is part of the Ly6/uPAR superfamily. This protein is characterized by a LU domain, a structural motif that includes disulfide bonds forming a three-fingered shape, similar to those found in snake venom neurotoxins (Loughner2016Organization). LY6K is a glycosylphosphatidylinositol (GPI)-anchored protein, suggesting its localization to the cell membrane, where it plays a role in cellular interactions and signaling pathways (Guo2022A). It is primarily expressed in testicular germ cells, where it may facilitate sperm cell migration, indicating its involvement in reproductive processes (Wang2024LY6K). In pathological contexts, LY6K is notably upregulated in various cancers, including bladder cancer, ovarian cancer, glioblastoma, and lung adenocarcinoma, where it contributes to tumorigenic processes and is considered a potential therapeutic target (Geng2022Downregulation; Matsuda2010LY6K).

## Structure
LY6K is a protein that belongs to the Ly6/uPAR superfamily, characterized by the presence of a LU domain. This domain typically includes disulfide bonds that form a three-fingered structural motif, similar to snake venom neurotoxins (Loughner2016Organization). The LU domain in LY6K spans amino acids 58-138, which are crucial for its interaction with the TGF-β receptor complex, specifically binding to the TbR1 receptor (AndrysOlek2023Experimental).

The protein structure of LY6K has been modeled using computational methods such as I-TASSER and AlphaFold2, which have provided insights into its conformation and interaction sites. These models suggest that the protein's loop regions exhibit mobility, which may influence its binding interactions (AndrysOlek2023Experimental). The AlphaFold2 model, in particular, identified specific residues, such as 127-130, that interact with TbR1, while other residues like 91, 93-95, and 113-121 are involved in interactions with TbR2 (AndrysOlek2023Experimental).

LY6K is a glycoprotein, indicating that it may undergo post-translational modifications such as glycosylation, which could affect its stability and interactions (AndrysOlek2023Experimental). The protein is expressed in a cancer-specific manner, making it a potential target for therapeutic interventions.

## Function
LY6K, a member of the Ly6/uPAR superfamily, is primarily expressed in testicular germ cells in healthy human tissues, where it may play a role in promoting sperm cell migration, indicating its involvement in reproductive processes (Wang2024LY6K). The protein is characterized by a conserved LU domain formed by cysteine residues creating disulfide bonds, which is typical of the Ly6/uPAR family (Wang2024LY6K). This domain is involved in various cellular functions, including cell proliferation, migration, and cell-cell interaction (Loughner2016Organization).

LY6K is a glycosylphosphatidylinositol (GPI)-anchored protein, suggesting its localization to the cell membrane, where it may interact with other molecules to influence cellular behavior (Guo2022A). The protein's activity in normal cells is limited to specific tissues, indicating a specialized function (Wang2024LY6K). While the precise molecular mechanisms of LY6K in healthy human cells remain to be fully elucidated, its expression in testicular germ cells and potential role in sperm cell migration highlight its importance in reproductive biology (Wang2024LY6K). Further research is needed to explore its function in healthy human cells and its potential as a therapeutic target (Guo2022A).

## Clinical Significance
The LY6K gene is implicated in several cancers, including bladder cancer, ovarian cancer, glioblastoma, and lung adenocarcinoma. In bladder cancer, LY6K is significantly upregulated due to gene amplification, contributing to increased cell growth, migration, and invasion. Knockdown of LY6K in bladder cancer cell lines results in decreased tumorigenic capabilities, highlighting its potential as a therapeutic target (Matsuda2010LY6K).

In ovarian cancer, high LY6K expression is associated with poor prognosis and is particularly elevated in recurrent cases. The gene is negatively regulated by miR-324-3p, and its downregulation leads to reduced tumor growth and aggressiveness (Geng2022Downregulation).

LY6K also plays a role in glioblastoma, where it enhances tumorigenicity through the ERK1/2 signaling pathway, mediated by its interaction with caveolin-1. This interaction is crucial for LY6K's function in promoting tumor growth and resistance to radiation therapy (Sastry2020LY6K).

In lung adenocarcinoma, the long non-coding RNA LY6K-AS, associated with LY6K, is identified as a prognostic biomarker and regulator of mitotic progression, suggesting its involvement in cancer progression and potential as a therapeutic target (Ali2021LY6KAS).

## Interactions
LY6K interacts with the TGF-β receptor complex, specifically binding to the TbR1 receptor. This interaction involves LY6K residues 58-138, located in the LU domain, which are sufficient for binding to TbR1. Computational models, including I-TASSER and AlphaFold2, have identified specific amino acid residues on LY6K that interact with both TbR1 and TbR2, supporting the experimental findings (AndrysOlek2023Experimental). The interaction of LY6K with the TGF-β receptor complex is significant in modulating TGF-β signaling, which plays a crucial role in cancer cell signaling and the tumor microenvironment (AndrysOlek2023Experimental).

In glioblastoma, LY6K enhances ERK1/2 signaling through its interaction with caveolin-1 (CAV-1), a major component of caveolae. This interaction is crucial for LY6K's role in promoting tumorigenicity in glioblastoma stem cells. The presence of a glycosylphosphatidylinositol (GPI) anchor is necessary for LY6K's membrane localization and its interaction with CAV-1, which facilitates ERK1/2 signaling (Sastry2020LY6K). These interactions highlight LY6K's involvement in critical signaling pathways that contribute to cancer progression.


## References


[1. (Geng2022Downregulation) Li Geng, Zhongqiu Wang, and Yongju Tian. Down-regulation of znf252p-as1 alleviates ovarian cancer progression by binding mir-324-3p to downregulate ly6k. Journal of Ovarian Research, January 2022. URL: http://dx.doi.org/10.1186/s13048-021-00933-7, doi:10.1186/s13048-021-00933-7. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13048-021-00933-7)

[2. (Matsuda2010LY6K) R Matsuda, H Enokida, T Chiyomaru, N Kikkawa, T Sugimoto, K Kawakami, S Tatarano, H Yoshino, K Toki, Y Uchida, K Kawahara, K Nishiyama, N Seki, and M Nakagawa. Ly6k is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling. British Journal of Cancer, 104(2):376–386, November 2010. URL: http://dx.doi.org/10.1038/sj.bjc.6605990, doi:10.1038/sj.bjc.6605990. This article has 40 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.bjc.6605990)

[3. (Sastry2020LY6K) Namratha G Sastry, Xuechao Wan, Tianzhi Huang, Angel A Alvarez, Rajendra P Pangeni, Xiao Song, Charles David James, Craig M Horbinski, Cameron W Brennan, Ichiro Nakano, Bo Hu, and Shi-Yuan Cheng. Ly6k promotes glioblastoma tumorigenicity via cav-1–mediated erk1/2 signaling enhancement. Neuro-Oncology, 22(9):1315–1326, February 2020. URL: http://dx.doi.org/10.1093/neuonc/noaa032, doi:10.1093/neuonc/noaa032. This article has 15 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/neuonc/noaa032)

[4. (Ali2021LY6KAS) Mohamad Moustafa Ali, Mirco Di Marco, Sagar Mahale, Daniel Jachimowicz, Subazini Thankaswamy Kosalai, Silke Reischl, Luisa Statello, Kankadeb Mishra, Catarina Darnfors, Meena Kanduri, and Chandrasekhar Kanduri. Ly6k-as lncrna is a lung adenocarcinoma prognostic biomarker and regulator of mitotic progression. Oncogene, 40(13):2463–2478, March 2021. URL: http://dx.doi.org/10.1038/s41388-021-01696-7, doi:10.1038/s41388-021-01696-7. This article has 19 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41388-021-01696-7)

[5. (Loughner2016Organization) Chelsea L. Loughner, Elspeth A. Bruford, Monica S. McAndrews, Emili E. Delp, Sudha Swamynathan, and Shivalingappa K. Swamynathan. Organization, evolution and functions of the human and mouse ly6/upar family genes. Human Genomics, April 2016. URL: http://dx.doi.org/10.1186/s40246-016-0074-2, doi:10.1186/s40246-016-0074-2. This article has 158 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s40246-016-0074-2)

[6. (Guo2022A) Dandan Guo, Yujia Liu, Yuchen Jiang, Shuilian Zheng, Tong Xu, Jiazhen Zhu, Pengcheng Chen, Ping Huang, and Yiwen Zhang. A narrative review of the emerging role of lymphocyte antigen 6 complex locus k in cancer: from basic research to clinical practice. Annals of Translational Medicine, 10(1):26–26, January 2022. URL: http://dx.doi.org/10.21037/atm-21-5831, doi:10.21037/atm-21-5831. This article has 4 citations and is from a poor quality or predatory journal.](https://doi.org/10.21037/atm-21-5831)

[7. (AndrysOlek2023Experimental) Justyna Andrys-Olek, Benson Chellakkan Selvanesan, Sheelu Varghese, Ricardo Hernandez Arriaza, Purushottam Babu Tiwari, Maksymilian Chruszcz, Tomasz Borowski, and Geeta Upadhyay. Experimental and computational studies reveal novel interaction of lymphocytes antigen 6k to tgf-β receptor complex. International Journal of Molecular Sciences, 24(16):12779, August 2023. URL: http://dx.doi.org/10.3390/ijms241612779, doi:10.3390/ijms241612779. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms241612779)

[8. (Wang2024LY6K) Yan Wang, Lin Liu, Na Li, Yijun Zong, Wei Liu, Wenhua Xu, Qi Wang, Peijuan Zhang, and Huiling Feng. Ly6k promotes proliferation and energy metabolism of lung adenocarcinoma cells by regulating aerobic glycolysis. Pakistan Journal of Zoology, 2024. URL: http://dx.doi.org/10.17582/journal.pjz/20221115081110, doi:10.17582/journal.pjz/20221115081110. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.17582/journal.pjz/20221115081110)